Altimmune, Inc. (ALT) Dividend History

Company News

• ALT Investors Have Opportunity to Join Altimmune, Inc. Fraud Investigation with the Schall Law Firm

  The Schall Law Firm is investigating potential securities law violations by Altimmune following a 52.18% stock drop after announcing Phase 2b trial results for pemvidutide, which were characterized as 'positive' but showed statistically insignificant improvements.

  Benzinga
• INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Altimmune, Inc. - ALT

  Pomerantz Law Firm is investigating potential securities fraud related to Altimmune's Phase 2b trial results for pemvidutide, which led to a 53.18% stock price drop after reporting statistically insignificant efficacy endpoints.

  GlobeNewswire Inc.
• Will Pfizer Will Acquire Altimmune or Viking Therapeutics After Its Obesity Pill Setback?

  Pfizer's experimental obesity drug danuglipron failed due to safety concerns, leading the company to consider acquiring Altimmune or Viking Therapeutics, which have promising obesity drug candidates. Pfizer may wait to see how its other obesity drug, PF-07976016, performs in clinical trials before making an acquisition decision.

  The Motley Fool

  Featured Companies: PFE VKTX
• The Zacks Analyst Blog Highlights Stocks recently featured in the blog include: Novo Nordisk, Eli Lilly's, Viking, Altimmune, Roche and Amgen

  Novo Nordisk, Eli Lilly's, Viking, Altimmune, Roche and Amgen are included in this Analyst Blog.

  Zacks Investment Research

  Featured Companies: AMGN LLY VKTX
• Five obesity-drug trends to watch in 2024: Who can compete with Eli Lilly and Novo Nordisk? 

  The obesity drugs that powered huge investor gains in 2023 are poised to inspire more corporate dealmaking, scientific breakthroughs and better patient access in the year ahead, analysts say.

  MarketWatch

  Featured Companies: AMGN LLY PFE VKTX